BioWorld

May 17, 2010

Pharma Outlicensing: From Opportunism to R&D Funding

A common theme heard around the hallways of the BIO 2010 International Convention earlier this month was that the big pharma firms in attendance were doing more selling than buying. Read More

Money Raised Year to Date

Savient for Sale, Ardea Bid Adds Dose: Gout on Move

German Plan: Blood in Water for Overseas Reimbursement?

Money Raised By Biotech in 2010

Week in Review

Word on the Street

FDA Approvals in April

Phase I Clinical Trials Update: April 2010

Phase II Clinical Trials Update: April 2010

Pivotal/Phase III Clinical Trials Update: April 2010

Non-U.S. Clinical Trials And Regulatory Actions: April 2010

FDA Submissions, Approvals And Other Actions: April 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...